Study Links Anemia Drugs To Increased Mortality Risk
The study, an analysis of more than 50 separate clinical trials, concluded that patients using so-called erythropoiesis-stimulating agents or ESAs raised their mortality risk by 10%. The study's authors said their findings raised concerns about the safety of prescribing ESAs to cancer patients.
“It looks pretty...
To view the full article, register now.